Idiopathic Intracranial Hypertension (Highly Investigational)
Highly investigational. Acetazolamide, weight loss, and (for vision-threatening cases) CSF shunting or optic nerve sheath fenestration remain primary; no evidence supports leech therapy for ICP.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for idiopathic intracranial hypertension. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Welche Evidenz existiert?
- Tier C (highly investigational). No controlled trials. Evidence-based first-line management is weight loss (which is often disease-modifying), acetazolamide (the Idiopathic Intracranial Hypertension Treatment Trial showed superiority over placebo), topiramate as alternative, and for sight-threatening or refractory disease optic nerve sheath fenestration, CSF shunting (VP or LP shunt), or venous sinus stenting. Vision must be monitored urgently — papilledema with field loss is the principal threat.
- Hauptrisiken
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Vision-threatening disease — any delay in proven therapy risks permanent blindness
- No mechanistic plausibility for leech effect on CSF dynamics
- Wer dies nicht in Betracht ziehen sollte
- Patients with papilledema and visual-field loss (need urgent neuro-ophthalmologic and possibly surgical intervention)
- Patients who have not been started on acetazolamide and a weight-management plan
- Patients with secondary causes of intracranial hypertension that have not been worked up
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Was Sie Ihren Kliniker fragen sollten
- Have I been started on acetazolamide at therapeutic doses?
- Has my weight management plan been optimized — including consideration of bariatric surgery if BMI is high?
- What is my current visual field status, and how often will it be checked?
- Has venous sinus stenosis been excluded by MRV?
- If vision is at risk, should I have CSF shunting or optic nerve sheath fenestration?
- What is the published evidence base for leeches in IIH (likely none)?
- Wann dringende medizinische Versorgung suchen
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Any new vision change — blurring, blackout, peripheral field loss, double vision
- Severe worsening of headache or new neurologic symptoms
- Pulsatile tinnitus worsening abruptly
Was dies NICHT bedeutet
- It does not mean leech therapy is FDA-cleared for IIH — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace acetazolamide, weight management, or surgical CSF diversion for sight-threatening disease.
- It does not affect CSF production or absorption — there is no mechanistic rationale.
- It does not prevent permanent vision loss, which is the principal risk in IIH.
- It does not have any RCT or case-series evidence in this condition.
Sicherheits-Querverweise
Clinical Profile
- Category
- neurological
- ICD-10
- G93.2
- Safety tier
- high
Evidence Summary
Idiopathic intracranial hypertension (IIH) is elevated intracranial pressure without identifiable cause, predominantly affecting women of childbearing age with obesity, presenting with headache, papilledema, and visual disturbance. Evidence-based management per the IIH Treatment Trial includes weight reduction, acetazolamide, and surgical intervention (CSF diversion, optic nerve sheath fenestration, venous sinus stenting) for vision-threatening disease. There is no clinical evidence supporting hirudotherapy for intracranial pressure modulation. Cervical hirudotherapy has been mentioned anecdotally in traditional-medicine literature, but the proposed mechanism via venous outflow modulation is highly speculative. Application carries no demonstrated benefit and standard risks. Visual outcome is the priority and must drive treatment decisions.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Krashenyuk AI (2010)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Acute or progressive visual deterioration (urgent neuro-ophthalmology referral)
- Severe papilledema requiring acute surgical intervention
- Venous sinus thrombosis (this is a different diagnosis; needs anticoagulation)
- Pregnancy (IIH frequently coincides; different management)
- Patient not on evidence-based therapy
Related Conditions
Cervical Radiculopathy
Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.
Lumbar Radiculopathy (Sciatica)
Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.
Migraine
Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.
Tension-Type Headache
Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.